New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
New trial presents and preclinical readouts set to shape the oncology landscape
Zydus’ experimental therapy demonstrates significant improvements in liver function and patient outcomes, signaling new hope in a disease …
Fresh guidelines and a reshaped regulatory framework pave the way for smoother clinical research, even as COVID-19 maintains …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Already a subscriber? Log in